Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

Kidney International

Volumn 74, Issue 5, 2008, Pages 641-648

  Boonen, Steven ^a,b   Sellmeyer, Deborah E ^c   Lippuner, Kurt ^d   Orlov Morozov, Alexander ^e   Abrams, Ken ^f   Mesenbrink, Peter ^f   Eriksen, Erik F ^f   Miller, Paul D ^g  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

^e Moscow Clinical Hospital N 23   (Russian Federation)

^f NOVARTIS PHARMA AG   (Switzerland)

^g University of Colorado Health Sciences Center   (United States)

Author keywords

Osteoporosis; Postmenopausal; Renal; Safety; Zoledronic acid

Indexed keywords

CREATININE; PLACEBO; PROTEIN; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG INFUSION; DRUG SAFETY; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEDICAL PARAMETERS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; CREATININE; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; KIDNEY; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RENAL INSUFFICIENCY; SAFETY; TIME FACTORS;

EID: 49749093393     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.193     Document Type: Article

References (27)

1. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85: 4118-4124.
2. Cranney A, Tugwell P, Adachi J et al. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517-523.
3. Bone HG, Hosking D, Devogelaer JP et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-1199.
4. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000; 42: 175-195.
5. Cramer JA, Amonkar MM, Hebborn A. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460.
6. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-661.
7. Croom KF, Scott LJ. Intravenous ibandronate: in the treatment of osteoporosis. Drugs 2006; 66: 1593-1601.
8. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid 5 mg for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
9. Lyles KW, Colón-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-1809.
10. Green JR, Seltenmeyer Y, Jaeggi KA. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997; 80: 225-230.
11. Weinman EJ, Patak RV. Acute renal failure in cancer patients. Oncology 1992; 6: 47-52.
12. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24: 19-38.
13. Markowitz GS, Appel GB, Fine PL et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172.
14. Chen T, Berenson J, Vescio R et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42: 1228-1236.
15. Skerjanec A, Berenson J, Hsu C et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003; 43: 154-162.
16. Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38: 617-627.
17. Zometa [package insert]. Zoledronic Acid Prescribing Information. Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2003.
18. Delanaye P, Radermecker RP, Rorive M et al. Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example. Nephrol Dial Transplant 2005; 20: 2024-2028.
19. European Agency for the Evaluation of Medicinal Products. http://www.emea.europa.eu/humandocs/PDFs/EPAR/aclasta/H-595-PI-en.pdf. Site accessed February 22nd, 2007.
20. Food and Drug Administration. http://www.fda.gov/cder/foi/label/2006/ 021223s012lbl.pdf. Site accessed, February 22nd, 2007.
21. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676-1679.
22. Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281-289.
23. Munier A, Gras V, Andrejak M et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005; 39: 1194-1197.
24. Ritch PS. Treatment of cancer-related hypercalcemia. Semin Oncol 1990; 17(2 Suppl 5): 26-33.
25. Knudsen LM, Hippe E, Hjorth M et al. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207-212.
26. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9(Suppl 4): 28-37.
27. Stevens LA, Coresh J, Greene T et al. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.